Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib - Concepedia

Concepedia

Publication | Closed Access

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

146

Citations

25

References

2014

Year

Inger S. Nijhof, Richard W.J. Groen, Willy A. Noort, Berris van Kessel, Regina de Jong-Korlaar, Joost M. Bakker, Jeroen J. Lammerts van Bueren, Paul W.H.I. Parren, Henk M. Lokhorst, Niels W.C.J. van de Donk,

Clinical Cancer Research

Abstract

Our results provide the first preclinical evidence for the benefit of daratumumab plus lenalidomide combination for lenalidomide- and bortezomib-refractory patients.

References

	Year	Citations

Page 1